Jonathan Lucchesi

Elevated levels of Interleukin (IL)-33 induce bone pathology but absence of IL-33 does not negatively impact normal bone homeostasis.

R. Benschop, Andrea P Martin, Hana E. Baker, 2016, Cytokine.

Pharmacological Evaluation of a Pegylated Urocortin-1 Peptide in Experimental Autoimmune Disease Models

K. Thirunavukkarasu, Charlie C Hu, Y. Ma, 2022, The Journal of Pharmacology and Experimental Therapeutics.

Defective enamel and bone development in sodium-dependent citrate transporter (NaCT) Slc13a5 deficient mice

J. Rong, Y. Ma, A. Irizarry, 2017, PloS one.

Inhibition of myostatin prevents microgravity-induced loss of skeletal muscle mass and strength

Alicia M. Ortega, L. Stodieck, T. Bateman, 2020, PloS one.

Time course of disassociation of bone formation signals with bone mass and bone strength in sclerostin antibody treated ovariectomized rats.

H. Bryant, Y. Ma, N. Bivi, 2017, Bone.

Efficacy of a sclerostin antibody compared to a low dose of PTH on metaphyseal bone healing

B. Macias, P. Aspenberg, A. Harvey, 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

A nondepleting anti-CD19 antibody impairs B cell function and inhibits autoimmune diseases

D. Witcher, C. Wiethoff, Y. Ma, 2023, JCI insight.